Business Wire

New Investment Tracker: EU Cleantech Investments Shatter Records; €7 Billion Invested in First Half of This Year

8.7.2021 10:49:00 EEST | Business Wire | Press release

Share

Cleantech for Europe, a new initiative created by Cleantech Group, supported by Breakthrough Energy, today presented its first ‘EU Quarterly Cleantech Briefing’. The analysis finds that in the first half of this year more than €7 billion of venture capital was invested in cleantech innovation in the European Union (EU). With six months remaining in 2021, this figure has already beaten the previous annual record for Europe, set just last year at €4.7 billion.

In view of this momentum, Cleantech for Europe will bring together top cleantech leaders from VCs, startups, academia, and civil society to build much-needed bridges with policymakers in Brussels and other European capitals. In a first instance, six leading cleantech venture capital firms, regarded as pioneers in financing innovative low-carbon companies, are joining the initiative. Other communities from start-ups, scale-ups, academia and civil society will join the initiative over time to build a future-oriented, technology-savvy group of cleantech leaders from across the EU.

The six “Cleantech for Europe Leaders” are: Beamline Accelerator (Estonia), btov Industrial Tech Fund (Germany), Inven Capital (Czech Republic), Munich Venture Partners (Germany), Rockstart (Netherlands), and SET Ventures (Netherlands). Combined, these firms have invested in more than 150 innovative low-carbon start-ups and scale-ups, including global leaders such as Sonnen in batteries and Sunfire in hydrogen production. For the first time, these firms are coming together to build a collective voice and convey to policymakers and other stakeholders the importance of investing in the next generation of clean technologies.

Despite the fact that EU cleantech investments are booming compared to previous years, the EU Quarterly Cleantech Briefing notes they may still fall short of what is needed to ensure EU start-ups can scale up across the continent. In the past decade, EU companies seeking to scale have often turned toward Asia or North America for larger markets, more abundant funding and ambitious public policies that accelerate their adoption.

“This analysis illustrates the extraordinary progress of the EU’s cleantech ecosystem – and the mountain of urgent work that lies ahead, particularly around helping build an EU policy framework that prioritizes and supports cleantech innovation.” said Ann Mettler, Vice President Europe at Breakthrough Energy, an organization founded by Bill Gates to support the innovations that will lead the world to net-zero emissions.

The release of the investment tracker and the announcement of the Cleantech for Europe initiative come just days before the EU prepares to unveil its highly anticipated “Fit for 55” package of climate legislation, and as most EU member states are finalizing Covid economic recovery plans that the European Commission has stipulated must include strong climate- and clean energy-related components.

The analysis also found: increasing numbers of late-stage deals; major deals of €300 million or more in industries including batteries, electric mobility, shared mobility and the circular economy; and a sharp uptick in the number of deals in the materials and chemicals sector. Sign up for future quarterly briefings here.

The involvement of top venture capital firms in the Cleantech for Europe initiative underscores how important policy is to the success of cleantech innovation.

“The goal of the new initiative is to place cleantech innovation at the center of EU public policy debates in the coming weeks, months and years,” said Jules Besnainou, director at Cleantech Group, a research and consulting company that is helping organize the new group and author the quarterly briefings. “We want the bloc to capitalize on opportunities to build and expand clean industries, ensure a just transition, and mount a stronger response to a climate crisis which grows more urgent by the day.”

“The regulatory framework is critical for success in cleantech. We see it in hydrogen: strong policy moves result in market uptake.” added Ivo Němejc, Vice Chairman of the Board of Directors, Inven Capital

“It is still very hard for EU cleantech start-ups to scale beyond their national borders. If we want to lead the race to net zero, we need to start building continental champions.” said Martin Kröner, Managing Partner, Munich Venture Partners

“The energy transition is a systemic challenge, but also an opportunity for the EU to lead the world on climate innovation while creating high-quality jobs.” added René Savelsberg, Managing Partner and Co-Founder, SET Ventures

“To reach climate leadership, we must improve the funding cycle for EU cleantech. The time to act is now.” said Christian Reitberger, Partner, btov Industrial Tech Fund

“Our success in Estonia proves that efficient cooperation between policy-makers and cleantech leaders is in fact a must for sustainable innovation development.” added Erki Ani, CEO, Beamline Accelerator

Additional venture capital firms are expected to join the group in the coming months.

Specifically, the Cleantech for Europe initiative calls on the EU to:

  • Create a demand shock for green solutions. Create sectoral transition plans. Implement a predictable and progressive price on carbon. Accelerate green public procurement.
  • Support the creation of at least 10 EU scale-up funds. Increase non-dilutive funding. Leverage public-private instruments such as carbon contracts for difference.
  • Support cross-border scaling. Harmonize regulations and standards to allow innovative companies scale from one country to the continent. Develop integrated value chains across all member states.

In unveiling the investment tracker, Cleantech for Europe also announced that it will hold an inaugural Cleantech for Europe Summit on September 8, featuring key leaders from Europe’s venture capital and policy communities. The Summit will be opened by Pascal Canfin, MEP and Chair of the Committee on the Environment, Public Health and Food Safety at the European Parliament. To participate in the Summit, sign up here.

To set up interviews with European venture capitalists and innovators active in the cleantech space, and policy experts, or to get more of the backstory on how and why the Cleantech for Europe initiative was conceived, please contact Jules Besnainou at hello@cleantechforeurope.com

About Cleantech for Europe
Cleantech for Europe is an initiative created by Cleantech Group, supported by Breakthrough Energy and leading EU cleantech investors. Our mission is to help the EU lead the race to net zero while creating long-term industrial competitiveness. We aim to put innovation at the center of the public policy debate and build bridges between the EU’s cleantech community and policymakers in Brussels and member states.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact:
Jules Besnainou, hello@cleantechforeurope.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye